Cosmetic cross-reference Noindex: medium evidence

Soy oil

CAS 8001-22-7

Soy oil (CAS 8001-22-7) is a pharmaceutical compound with 0 bioactivity targets and 162 adverse event associations.

SOURCE NLM DailyMed

Label records

0

SOURCE EMBL-EBI ChEMBL

Bioactivity

0

SOURCE DrugCentral

Adverse signals

162

SOURCE IUPHAR/BPS

PubMed IDs

0

SOURCE EPA DSSTox

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Soy oil

CAS Number

8001-22-7

Source Match

EPA DSSTox

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE DSSTox identifiers DTXSID8027660

Cross-Reference to Chemicals

Same-CAS substance identity is available in the industrial chemicals vertical.

Soy oil is linked to DTXSID8027660 in DSSTox identifiers.

View industrial chemical data →

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Soy oil used for in pharmaceutical contexts?

Soy oil (CAS 8001-22-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Soy oil?

Soy oil has 162 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Abdominal pain, Acidosis, Administration site nodule, Adrenal insufficiency, Amylase increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Soy oil also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Glycine Max Oil with EU status "permitted".

What clinical phase is Soy oil in?

No phase 1-4 clinical development badge is rendered for Soy oil because the matched compound identifier rows do not contain a max-phase value.